NYSE:GKOS
Glaukos Corporation Stock News
$107.98
+2.97 (+2.83%)
At Close: May 07, 2024
Glaukos (GKOS) Stock Hits 52-Week High: More Room to Grow?
09:39am, Friday, 14'th Jul 2023
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos: Revising To Buy On These 3 Catalytic Factors
06:13am, Friday, 16'th Jun 2023
Glaukos Corporation has 3 catalysts to price change going forward. These involve the company's performance, growth, and potential future developments. Revising to buy on fundamental, sentimental groun
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
10:43am, Friday, 19'th May 2023
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos' (GKOS) Q1 Earnings Beat Estimates, Sales Rise Y/Y
08:22am, Thursday, 04'th May 2023
Glaukos' (GKOS) Q1 revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to wider operating loss.
Glaukos Corporation (GKOS) Q1 2023 Earnings Call Transcript
10:53pm, Wednesday, 03'rd May 2023
Glaukos Corporation (NYSE:GKOS ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Chris Lewis – Vice President-Investor Relations and Corporate Affairs Tom Burns – Chai
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
08:32pm, Wednesday, 03'rd May 2023
Glaukos (GKOS) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.38 per share a year ago.
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
12:55pm, Monday, 03'rd Apr 2023
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos' (GKOS) Q4 Earnings Beat Estimates, Sales Decline Y/Y
12:03pm, Thursday, 23'rd Feb 2023
Glaukos' (GKOS) Q4 revenues beat estimates but fall year over year. Lower revenues, along with higher expenses, hurt margins.
Glaukos Corporation (GKOS) Q4 2022 Earnings Call Transcript
09:02pm, Wednesday, 22'nd Feb 2023
Glaukos Corporation (NYSE:GKOS ) Q4 2022 Earnings Conference Call February 22, 2023 4:30 PM ET Company Participants Chris Lewis – Vice President-Investor Relations and Corporate Affairs Tom Burns �
Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates
07:34pm, Wednesday, 22'nd Feb 2023
Glaukos (GKOS) delivered earnings and revenue surprises of 5.36% and 5.19%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
03:11pm, Friday, 06'th Jan 2023 Zacks Investment Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Analyst Expectations for Glaukos's Future
07:01pm, Wednesday, 28'th Dec 2022 Benzinga
Glaukos (NYSE:GKOS) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
2
4
1
0
Last 30D
0
1
0
3 Reasons to Retain Glaukos (GKOS) Stock in Your Portfolio
04:06pm, Wednesday, 28'th Dec 2022 Zacks Investment Research
Investors continue to be optimistic about Glaukos (GKOS) on the back of continued strength in its flagship iStent.
10 Analysts Have This to Say About Glaukos
04:01pm, Wednesday, 28'th Dec 2022 Benzinga
Within the last quarter, Glaukos (NYSE:GKOS) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
2
4
1
0
Last 30D
0
1
0
What 10 Analyst Ratings Have To Say About Glaukos
03:05pm, Wednesday, 28'th Dec 2022 Benzinga
Within the last quarter, Glaukos (NYSE:GKOS) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
2
4
1
0
Last 30D
0
1
0
